{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for angiotensin root_names_name in Any Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 347
(2016)
Source URL:
First approved in 1997
Source:
ANDA074164
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
First approved in 1997
Source:
M032
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NDA020701
(1997)
Source URL:
First approved in 1997
Source:
NDA020701
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT01426750: Phase 4 Interventional Completed Malnutrition
(2002)
Source URL:
First approved in 1996
Source:
ANDA091226
Source URL:
Class:
STRUCTURALLY DIVERSE
Conditions:
Phopsholipon is a well-established lipoid brand characterizes natural and hydrogenated lecithin fractions and phospholipids from soybean, rapeseed (canola) or sunflower for pharmaceutical oral or topical applications and for use in cosmetics, as well in emulsions; liposomal formulations; as natural oil replenishing agents in shampoos and bath additives. Applications: preparation of mixed micelles, liposomes and micro emulsions. Solubilizer for parenteral administration forms; emulsifier for pharmacy, dermatology and cosmetics; phosphatidylcholine source for drugs and dietetics.
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2005)
Source URL:
First approved in 1996
Source:
NDA020428
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 356
(1993)
Source URL:
First approved in 1993
Source:
21 CFR 356
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02796833: Phase 4 Interventional Completed Home Parenteral Nutrition
(2016)
Source URL:
First approved in 1993
Source:
ANDA210138
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M006
(2022)
Source URL:
First approved in 1991
Source:
505G(a)(3)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Chlorhexidine FLUSH by Stratford Care Usa, Inc.
(2011)
Source URL:
First approved in 1991
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M006
(2011)
Source URL:
First approved in 1991
Source:
NDA019885
Source URL:
Class:
STRUCTURALLY DIVERSE